1. New Lipid-Lowering Guidelines

3. Clinical Diagnosis of Metabolic Syndrome

4. Not Everyone Develops Diabetes

5. 2018 ACC/AHA Guidelines on the Management of Blood Cholesterol

6. Risk-Enhancing Factors for Primary Prevention*

7. Who Should Be on Statin Therapy?

8. Renal Insufficiency Is a Risk-Enhancing Factor for ASCVD

9. Risk of Developing NODM Meta-Analysis of Placebo-Controlled Statin Trials

10. Risk for T2DM Is Different Among Statins

11. T2DM Risk Increases With Statin Intensity Meta-Analysis of 5 Clinical Trials

12. Predisposing Factors for NODM

13. Reduced MACE With Continued Statin Therapy

14. Intensity of Statin Therapy

15. JUPITER Rosuvastatin Therapy and Diabetes Risk

16. Statin Use in Patients With Normoglycemic and Impaired Fasting Glucose

17. Pitavastatin Neutral Impact on Serum Glucose

18. Understanding Risk/Benefit

19. Primary Prevention Case

20. Coronary Artery Calcium

21. Lifestyle Modification Is a Cornerstone of Therapy for Patients With Metabolic Syndrome

22. Secondary Prevention Case

23. Secondary Prevention in Patients With Clinical ASCVD

24. REAL-CAD

25. REAL-CAD Low- vs High-Intensity Pitavastatin

26. Pitavastatin Head-to-Head Statin Trials

27. Team Clinician-Patient Discussion

28. Guideline Implementation

29. Interprofessional Cardiovascular Team-Based Care

30. Conclusion

31. Abbreviations

32. Abbreviations (cont)

33. Abbreviations (cont)